These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 35726143)
1. Impact of COVID-19 on Clinicopathological Spectrum of Pityriasis Rosea in Korea. Kim DH; Cho JH; Park SJ; Seo SH; Ahn HH J Korean Med Sci; 2022 Jun; 37(24):e190. PubMed ID: 35726143 [TBL] [Abstract][Full Text] [Related]
3. Pityriasis Rosea after COVID-19 Infection. Prtajin M; Ljubojević Hadžavdić S Acta Dermatovenerol Croat; 2022 Dec; 30(4):265-266. PubMed ID: 36919396 [TBL] [Abstract][Full Text] [Related]
4. A clinicoepidemiological study of pityriasis rosea in South India. Ganguly S Skinmed; 2013; 11(3):141-6. PubMed ID: 23930352 [TBL] [Abstract][Full Text] [Related]
5. Molecular study of recent virus and its relationship to Pityriasis rosea. Kawen AA J Popul Ther Clin Pharmacol; 2022; 29(1):e109-e115. PubMed ID: 35686902 [TBL] [Abstract][Full Text] [Related]
6. Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. Drago F; Broccolo F; Ciccarese G Clin Dermatol; 2022; 40(5):586-590. PubMed ID: 35093476 [TBL] [Abstract][Full Text] [Related]
7. Pityriasis Rosea Recurrence is Much Higher than Previously Known: A Prospective Study. Yüksel M Acta Derm Venereol; 2019 Jun; 99(7):664-667. PubMed ID: 30848285 [TBL] [Abstract][Full Text] [Related]
8. Oropharyngeal lesions in pityriasis rosea. Ciccarese G; Broccolo F; Rebora A; Parodi A; Drago F J Am Acad Dermatol; 2017 Nov; 77(5):833-837.e4. PubMed ID: 28728872 [TBL] [Abstract][Full Text] [Related]
9. Pityriasis Rosea in Kaduna, North-West Nigeria: A 20-Year Experience. Yahya H West Afr J Med; 2023 Jul; 40(7):704-710. PubMed ID: 37515778 [TBL] [Abstract][Full Text] [Related]
10. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. Cohen OG; Clark AK; Milbar H; Tarlow M Hum Vaccin Immunother; 2021 Nov; 17(11):4097-4098. PubMed ID: 34435935 [TBL] [Abstract][Full Text] [Related]
11. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: A systematic review. Khan I; Elsanousi AA; Shareef AM; Tebha SS; Arif A; Gul S Immun Inflamm Dis; 2023 Apr; 11(4):e804. PubMed ID: 37102660 [TBL] [Abstract][Full Text] [Related]
14. Pityriasis Rosea Associated With COVID-19 Vaccination: A Common Rash Following Administration of a Novel Vaccine. Valk B; Bender B Cutis; 2021 Dec; 108(6):317-318. PubMed ID: 35167784 [TBL] [Abstract][Full Text] [Related]
15. The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease. Dursun R; Temiz SA Dermatol Ther; 2020 Jul; 33(4):e13730. PubMed ID: 32475003 [TBL] [Abstract][Full Text] [Related]
16. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review. Wang CS; Chen HH; Liu SH J Formos Med Assoc; 2022 May; 121(5):1003-1007. PubMed ID: 35012825 [TBL] [Abstract][Full Text] [Related]
17. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature. Buckley JE; Landis LN; Rapini RP JAAD Int; 2022 Jun; 7():164-168. PubMed ID: 35156062 [TBL] [Abstract][Full Text] [Related]
18. Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: A case report. Birlutiu V; Birlutiu RM; Iancu GM Medicine (Baltimore); 2021 Apr; 100(14):e25352. PubMed ID: 33832113 [TBL] [Abstract][Full Text] [Related]
19. The pityriasis rosea calendar: a 7 year review of seasonal variation, age and sex distribution. Ayanlowo O; Akinkugbe A; Olumide Y Nig Q J Hosp Med; 2010; 20(1):29-31. PubMed ID: 20450028 [TBL] [Abstract][Full Text] [Related]
20. Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Potestio L; Martora F; Cacciapuoti S; Megna M; Villani A; Ruggiero A Clin Cosmet Investig Dermatol; 2024; 17():51-57. PubMed ID: 38222859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]